Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.
This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.
Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.
Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.
Give it a listen


A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....
At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...